Regenerative Treatment Matching Ladder
Match treatment intensity to injury type and systemic need
- Difficulty
- Moderate
- Time to result
- ~weeks to results
- Steps
- 5
- Confidence
- 92%
The treatment-matching ladder begins by classifying the problem on two axes: acute versus chronic, and local versus systemic. An acute muscle or tendon tear may fit PRP because it promotes an inflammatory repair response and can shorten a healing window. A local soft-tissue injury may instead call for exosomes plus peptides, which Khan says target complementary signaling pathways without requiring a large stem-cell dose. Culture-expanded intravenous stem cells sit higher on the ladder and are reserved for chronic inflammation, autoimmune conditions, or severe osteoarthritis where systemic immune regulation or a larger cell dose is relevant. The framework also rejects modality names as sufficient evidence: dose, cell expansion, passage count, manufacturing quality, jurisdiction, and clinician expertise materially affect the treatment. The decision ends with functional tracking—pain, movement, recovery, or measured body composition—not promotional claims alone.
Origin
Dr. Adeel Khan contrasted how he selects PRP, exosomes, peptides, and culture-expanded stem cells for acute injuries, chronic degeneration, and systemic inflammation.
Core principles
- 01Use the least intensive modality that fits the condition
- 02Distinguish acute tissue damage from chronic degeneration
- 03Separate local injuries from systemic inflammatory problems
- 04Dose and manufacturing quality determine whether advanced therapies are meaningful
- 05Combine modalities only when they target different pathways
How to run it
- 1
Classify the condition
Determine whether the problem is acute or chronic and local or systemic. This classification narrows the appropriate level and mechanism of treatment.
Pro tip Write the classification explicitly before discussing products or procedures.
Watch out Starting with a favored treatment creates a one-size-fits-all recommendation.
- 2
Match the lowest suitable rung
Use PRP for selected acute muscle or tendon tears, and consider exosomes plus peptides for many local soft-tissue injuries. Do not escalate merely because a more expensive modality is available.
Pro tip Ask which biological pathway each proposed component targets.
Watch out PRP quality varies with the patient's blood and age.
- 3
Reserve systemic treatment
Consider culture-expanded intravenous stem cells when the target is systemic immune regulation, chronic inflammation, autoimmune disease, or sufficiently advanced degeneration. Confirm that the proposed dose is meaningful for the intended route.
Pro tip Ask for the cell count and why that dose fits the condition.
Watch out A very low intravenous cell dose may be clinically meaningless.
- 4
Audit product quality
Examine donor screening, culture expansion, passage count, storage, and manufacturing controls. These factors affect potency, stability, survival, and potential inflammatory harm.
Pro tip Request concrete manufacturing specifications instead of accepting terms such as premium or potent.
Watch out Excessive replication can leave unstable or senescent cells.
- 5
Measure practical outcomes
Track the functional result that justified treatment, such as pain, range of motion, return to activity, or body composition. Use biomarkers as supporting information rather than the sole verdict.
Pro tip Capture a baseline before treatment so change can be evaluated.
Watch out A biomarker change does not automatically mean the patient feels or functions better.
In the wild
An athlete presents the day after an acute tendon tear and wants the most advanced treatment available. The clinician classifies it as acute and local, evaluates severity, and selects PRP to support repair rather than escalating automatically to intravenous stem cells. Recovery time and return to sport are recorded against a baseline.
→ Treatment intensity stays proportionate to the injury and success is judged by function.
An older patient has a chronic inflammatory condition rather than a single fresh injury. The clinician evaluates systemic options, verifies that any proposed stem cells are culture-expanded at an appropriate dose, reviews manufacturing controls, and compares the plan with lower-cost alternatives before proceeding.
→ The modality is selected for systemic immune effects rather than because stem cells are the clinic's default product.
Common mistakes
Using stem cells for everything
This ignores whether the problem is acute, chronic, local, or systemic. It can expose patients to unnecessary cost and risk.
Ignoring dose and manufacturing
The treatment label does not reveal whether the product is potent, stable, or appropriately dosed. Product quality is part of the decision, not an implementation detail.
Measuring biomarkers alone
A laboratory or biological-age result can be debated or misinterpreted. Pair it with the functional outcome the patient actually sought.
Is it for you?
Best for
Clinician-led comparisons of PRP, exosomes, peptides, and stem cells for injuries or systemic inflammatory conditions.
Not ideal for
Self-treatment, diagnosis without a clinician, or conditions requiring established emergency or surgical care.
From the transcript
“But if it's just an injury for like a tendon or a muscle or a nerve, then we just use exosomes because exosomes they have…”
“But, it's not good for chronic degenerative conditions, which is what most of society is dealing with. And And so, that's where stem cells and…”
“But if you do the full package and there's a lot of stuff that we do, you could spend up to 50,000, 75,000 dollars.”
From the episode
Episode 357: The Future of Anti-Aging: Dr. Adeel Khan's Insights on Gene Therapy, Stem Cells, and Exosomes